Symbols / ANVS Stock $1.75 +0.57% Annovis Bio, Inc.

Healthcare • Biotechnology • United States • NYQ
ANVS (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Maria L. Maccecchini Ph.D.
Exch · Country NYQ · United States
Market Cap 74.45M
Enterprise Value 30.09M
Income -28.85M
Sales —
FCF (ttm) -15.18M
Book/sh 0.62
Cash/sh 0.69
Employees 7
Insider 10d —
IPO Jan 29, 2020
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -1.51
PEG —
P/S —
P/B 2.82
P/C —
EV/EBITDA —
EV/Sales —
Quick Ratio 5.37
Current Ratio 5.80
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -1.71
EPS next Y -1.16
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-15
Earnings (prior) 2026-05-15
ROA -106.03%
ROE -220.61%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 42.54M
Shs Float 25.10M
Insider Own 14.10%
Instit Own 16.71%
Short Float 12.95%
Short Ratio 4.12
Short Interest 5.02M
52W High 5.50
vs 52W High -68.18%
52W Low 1.54
vs 52W Low 13.64%
Beta 1.19
Impl. Vol. 3.72%
Rel Volume 0.93
Avg Volume 1.18M
Volume 1.09M
Target (mean) $12.50
Tgt Median $12.50
Tgt Low $8.00
Tgt High $17.00
# Analysts 2
Recom None
Prev Close $1.74
Price $1.75
Change 0.57%
About

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$12.50
Mean price target
2. Current target
$1.75
Latest analyst target
3. DCF / Fair value
$-6.42
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.75
Low
$8.00
High
$17.00
Mean
$12.50

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-14 main Canaccord Genuity Buy → Buy $17
2025-09-30 main Canaccord Genuity Buy → Buy $17
2025-09-03 main HC Wainwright & Co. Buy → Buy $10
2025-06-09 main HC Wainwright & Co. Buy → Buy $12
2025-05-15 main Canaccord Genuity Buy → Buy $17
2025-02-10 down D. Boral Capital Buy → Hold —
2024-11-11 main D. Boral Capital Buy → Buy $21
2024-11-11 reit HC Wainwright & Co. Buy → Buy $30
2024-10-25 up Maxim Group Hold → Buy $25
2024-08-15 main EF Hutton Buy → Buy $21
2024-08-15 reit HC Wainwright & Co. Buy → Buy $30
2024-08-13 init EF Hutton — → Buy $21
2024-07-17 reit HC Wainwright & Co. Buy → Buy $30
2024-07-11 main HC Wainwright & Co. Buy → Buy $30
2024-07-02 reit Rodman & Renshaw Buy → Buy $67
2024-06-12 reit HC Wainwright & Co. Buy → Buy $23
2024-06-04 init Rodman & Renshaw — → Buy $67
2024-05-13 main HC Wainwright & Co. Buy → Buy $23
2024-04-30 main Canaccord Genuity Buy → Buy $26
2024-04-30 reit HC Wainwright & Co. Buy → Buy $30
News
RSS: Latest ANVS news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-05-20 HOFFMAN MICHAEL B Director — 76,344 $1.75 $142,779
2026-04-02 HOFFMAN MICHAEL B Director — 713,800 $2.10 $1,498,980
2025-12-08 HOFFMAN MICHAEL B Director — 45,000 $4.24 $193,794
2025-11-24 HOFFMAN MICHAEL B Director — 39,200 $3.85 $159,886
2025-11-24 HOFFMAN MICHAEL B Director — 39,200 $3.85 $159,886
2025-11-21 HOFFMAN MICHAEL B Director — 20,000 $3.49 $69,900
2025-11-14 HOFFMAN MICHAEL B Director — 15,000 $2.11 $31,650
2025-10-28 MACCECCHINI MARIA-LUISA Chief Executive Officer — 97,561 $2.05 $200,000
2025-10-28 HOFFMAN MICHAEL B Director — 975,610 $2.05 $2,000,000
2025-09-10 BRUCK CLAUDINE Director — 7,142 $0.14 $1,000
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
29.70
+11.24%
26.69
-40.72%
45.04
+76.53%
25.51
Research And Development
25.22
+26.11%
20.00
-48.45%
38.79
+134.87%
16.52
Selling General And Administration
4.48
-33.13%
6.70
+7.29%
6.24
-30.58%
9.00
General And Administrative Expense
4.48
-33.13%
6.70
+7.29%
6.24
-30.58%
9.00
Other Gand A
4.48
-33.13%
6.70
+7.29%
6.24
-30.58%
9.00
Other Operating Expenses
—
—
—
—
Total Expenses
29.70
+11.24%
26.69
-40.72%
45.04
+76.53%
25.51
Operating Income
-29.70
-11.24%
-26.69
+40.72%
-45.04
-76.53%
-25.51
Total Operating Income As Reported
-29.70
-11.24%
-26.69
+40.72%
-45.04
-76.53%
-25.51
EBITDA
-29.70
-11.24%
-26.69
+40.72%
-45.04
-76.53%
-25.51
Normalized EBITDA
-29.84
+1.59%
-30.32
+8.67%
-33.20
-30.13%
-25.51
EBIT
-29.70
-11.24%
-26.69
+40.72%
-45.04
-76.53%
-25.51
Total Unusual Items
0.14
-96.08%
3.63
+130.63%
-11.84
—
Total Unusual Items Excluding Goodwill
0.14
-96.08%
3.63
+130.63%
-11.84
—
Net Income
-28.85
-17.34%
-24.59
+56.25%
-56.20
-121.90%
-25.33
Pretax Income
-28.85
-17.34%
-24.59
+56.25%
-56.20
-121.90%
-25.33
Net Non Operating Interest Income Expense
0.70
+145.95%
-1.52
-327.78%
0.67
+265.55%
0.18
Net Interest Income
0.70
+145.95%
-1.52
-327.78%
0.67
+265.55%
0.18
Interest Income Non Operating
0.70
+110.66%
0.33
-50.31%
0.67
+265.55%
0.18
Interest Income
0.70
+110.66%
0.33
-50.31%
0.67
+265.55%
0.18
Other Income Expense
0.14
-96.08%
3.63
+130.63%
-11.84
—
Gain On Sale Of Security
0.14
-96.08%
3.63
+130.63%
-11.84
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-28.85
-17.34%
-24.59
+56.25%
-56.20
-121.90%
-25.33
Net Income From Continuing Operation Net Minority Interest
-28.85
-17.34%
-24.59
+56.25%
-56.20
-121.90%
-25.33
Net Income From Continuing And Discontinued Operation
-28.85
-17.34%
-24.59
+56.25%
-56.20
-121.90%
-25.33
Net Income Continuous Operations
-28.85
-17.34%
-24.59
+56.25%
-56.20
-121.90%
-25.33
Normalized Income
-29.00
-2.76%
-28.22
+36.40%
-44.37
-75.17%
-25.33
Net Income Common Stockholders
-28.85
-17.34%
-24.59
+56.25%
-56.20
-121.90%
-25.33
Diluted EPS
-1.40
+39.39%
-2.31
+62.92%
-6.23
-100.97%
-3.10
Basic EPS
-1.40
+30.69%
-2.02
+67.58%
-6.23
-100.97%
-3.10
Basic Average Shares
20.55
+68.70%
12.18
+35.01%
9.02
+10.55%
8.16
Diluted Average Shares
20.55
+67.97%
12.24
+35.60%
9.02
+10.55%
8.16
Diluted NI Availto Com Stockholders
-28.85
-2.26%
-28.22
+49.80%
-56.20
-121.90%
-25.33
Average Dilution Earnings
0.00
+100.00%
-3.63
0.00
—
Provision For Doubtful Accounts
—
—
0.00
0.00
Total Other Finance Cost
—
1.85
—
—
Line Item Trend 2023-12-31
Total Assets
10.21
Current Assets
10.21
Cash Cash Equivalents And Short Term Investments
5.75
Cash And Cash Equivalents
5.75
Prepaid Assets
4.45
Total Non Current Assets
0.00
Total Liabilities Net Minority Interest
17.96
Current Liabilities
4.28
Payables And Accrued Expenses
4.28
Payables
1.29
Accounts Payable
1.29
Current Accrued Expenses
2.99
Total Non Current Liabilities Net Minority Interest
13.68
Stockholders Equity
-7.75
Common Stock Equity
-7.75
Capital Stock
0.00
Common Stock
0.00
Preferred Stock
0.00
Share Issued
10.52
Ordinary Shares Number
10.52
Treasury Shares Number
0.00
Additional Paid In Capital
102.51
Retained Earnings
-110.26
Total Equity Gross Minority Interest
-7.75
Total Capitalization
-7.75
Working Capital
5.93
Invested Capital
-7.75
Net Tangible Assets
-7.75
Tangible Book Value
-7.75
Derivative Product Liabilities
13.68
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-25.62
-17.01%
-21.89
+45.22%
-39.97
-130.85%
-17.31
Cash Flow From Continuing Operating Activities
-25.62
-17.01%
-21.89
+45.22%
-39.97
-130.85%
-17.31
Net Income From Continuing Operations
-28.85
-17.34%
-24.59
+56.25%
-56.20
-121.90%
-25.33
Other Non Cash Items
—
1.80
—
—
Stock Based Compensation
1.80
-53.15%
3.84
-17.10%
4.63
-49.43%
9.15
Operating Gains Losses
-0.14
+96.08%
-3.63
-130.63%
11.84
—
Gain Loss On Investment Securities
-0.14
+96.08%
-3.63
-130.63%
11.84
—
Change In Working Capital
1.58
+131.60%
0.68
+398.21%
-0.23
+79.89%
-1.14
Change In Receivables
—
—
—
—
Change In Prepaid Assets
1.82
+68.96%
1.08
-66.16%
3.19
+143.54%
-7.33
Change In Payables And Accrued Expense
-0.25
+38.31%
-0.40
+88.36%
-3.42
-155.22%
6.19
Change In Accrued Expense
-0.53
+62.43%
-1.41
-87.91%
-0.75
-125.73%
2.92
Change In Payable
0.28
-71.91%
1.01
+137.97%
-2.67
-181.52%
3.27
Change In Account Payable
0.28
-71.91%
1.01
+137.97%
-2.67
-181.52%
3.27
Financing Cash Flow
34.60
+29.63%
26.69
+53.89%
17.34
+375888.10%
0.00
Cash Flow From Continuing Financing Activities
34.60
+29.63%
26.69
+53.89%
17.34
+375888.10%
0.00
Net Common Stock Issuance
34.60
+85.35%
18.67
+10.55%
16.89
0.00
Proceeds From Stock Option Exercised
0.00
-99.98%
8.03
+1650.71%
0.46
+9836.81%
0.00
Changes In Cash
8.98
+87.20%
4.80
+121.20%
-22.62
-30.71%
-17.31
Beginning Cash Position
10.55
+83.36%
5.75
-79.72%
28.38
-37.89%
45.69
End Cash Position
19.53
+85.11%
10.55
+83.36%
5.75
-79.72%
28.38
Free Cash Flow
-25.62
-17.01%
-21.89
+45.22%
-39.97
-130.85%
-17.31
Common Stock Issuance
34.60
+85.35%
18.67
+10.55%
16.89
0.00
Issuance Of Capital Stock
34.60
+85.35%
18.67
+10.55%
16.89
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category